

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
17/LO/0825	223457	Randomised, Phase 2 , double blind, placebo controlled study to assess the safety and efficacy of Filgotinib, GS-9876 and GS-4059 in adult subjects with Active Sjogren's syndrome	Number Agreed	2	2	Date Agreed	22/04/2018	0	05/09/2018	0	Recruitment Finished
14/SC/1161	155743	E-Ulimaster registry	Number Agreed	30	30	Date Agreed	01/12/2015	250	02/05/2018	391	Recruitment Finished
15/LO/0769	155035	Left Atrial Appendage Occlusion Study II (LAAOS III)	Range Agreed	2	50	Date Agreed	01/06/2018	13	08/06/2018	13	Recruitment Finished
17/LO/0736	225746	CN2002012	Number Agreed	5	5	Date Agreed	27/07/2018	1	27/07/2018	1	Recruitment Finished
17/EM/0361	234065	215MS202 Efficacy & Safety of BIIB033 as an Add-on Therapy in RMS	Number Agreed	2	2	Not Available / Not Agreed			17/08/2018	0	Recruitment Finished
18/WM/0017	236521	Post-Market Clinical Investigation of the Clareon® IOL	Number Agreed	10	10	Not Available / Not Agreed			28/09/2018	13	Recruitment Finished
17/EM/0281	229054	204862 Phase 3 switch study -TAF regimen to DTG + 3TC in HIV-1 adults	Range Agreed	5	10	Not Available / Not Agreed			10/05/2018	1	Recruitment Finished
16/SC/0416	210405	D5290C00003 - MEDI8897 Against RSV in Healthy Preterm Infants	Range Agreed	2	5	Date Agreed	30/11/2017	5	30/11/2018	5	Recruitment Finished

17/EE/0431	234555	A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose- Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination with Doravirine (DOR) and Lamivudine	Number Agreed	4	4	Date Agreed	31/03/2018	1	20/04/2018	1	Recruitment Finished
18/NE/0132	242937	"A PHASE III, RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB & CHEMOTHERAPY IN PATIENTS WITH HER2 P	Range Agreed	4	8	Date Agreed	01/07/2019	5	24/12/2018	5	Recruitment Finished
17/YH/0228	222492	CALM- 2 – CONTROLLING AND LOWERING BLOOD PRESSURE WITH THE MOBIUSHD®	Number Agreed	2	2	Date Agreed	31/05/2019	0	19/02/2019	0	Withdrawn By Host